华润双鹤：全资子公司复方醋酸钠林格注射液获批上市

Core Viewpoint - China Resources Double Crane announced that its wholly-owned subsidiary, Jingxi Double Crane, received the drug registration certificate for Compound Sodium Acetate Ringer's Injection from the National Medical Products Administration, indicating successful consistency evaluation [1] Group 1: Product Development - The drug is intended for supplementing extracellular fluid and correcting metabolic acidosis, with research and development initiated in October 2022 and approval granted on January 20, 2026 [1] - The total R&D investment for this drug amounted to 3.8353 million yuan [1] Group 2: Market Potential - The projected total sales of related drugs in China for 2024 is 1.149 billion yuan, with the top three companies being Jiangsu Zhengda Fenghai, Nanjing Zhengda Tianqing, and Sichuan Kelun Pharmaceutical [1] - The approval of this drug will enrich the product line for the company, although sales remain uncertain [1]